137 related articles for article (PubMed ID: 32378563)
1. Cancer Cachexia May Hinder Pain Control When Using Fentanyl Patch.
Chiba T; Takahashi H; Tairabune T; Kimura S; Ueda H; Kudo K
Biol Pharm Bull; 2020; 43(5):873-878. PubMed ID: 32378563
[TBL] [Abstract][Full Text] [Related]
2. Clinical experience with transdermal and orally administered opioids in palliative care patients--a retrospective study.
Clemens KE; Klaschik E
Jpn J Clin Oncol; 2007 Apr; 37(4):302-9. PubMed ID: 17519302
[TBL] [Abstract][Full Text] [Related]
3. A retrospective study on the influence of nutritional status on pain management in cancer patients using the transdermal fentanyl patch.
Takahashi H; Chiba T; Tairabune T; Kimura Y; Wakabayashi G; Takahashi K; Kudo K
Biol Pharm Bull; 2014; 37(5):853-7. PubMed ID: 24790008
[TBL] [Abstract][Full Text] [Related]
4. Opioid rotation from transdermal fentanyl to continuous subcutaneous hydromorphone in a cachectic patient: A case report and review of the literature.
Jackson LD; Wortzman R; Chua D; Selby D
J Oncol Pharm Pract; 2021 Jan; 27(1):238-243. PubMed ID: 32501183
[TBL] [Abstract][Full Text] [Related]
5. Risk Factors for Poor Pain Control after Opioid Switching from Oxycodone Tablet to Fentanyl Patch.
Morikawa N; Kasahara Y; Takahashi Y; Nishikura K; Nishihara M
Biol Pharm Bull; 2019; 42(10):1674-1678. PubMed ID: 31582655
[TBL] [Abstract][Full Text] [Related]
6. Unusual case of transdermal fentanyl in cachexia.
Lam D; Kay S; Pickard J; Harrison S
BMJ Support Palliat Care; 2019 Dec; 9(4):363-364. PubMed ID: 30612090
[TBL] [Abstract][Full Text] [Related]
7. Transdermal fentanyl in cachectic cancer patients.
Heiskanen T; Mätzke S; Haakana S; Gergov M; Vuori E; Kalso E
Pain; 2009 Jul; 144(1-2):218-22. PubMed ID: 19442446
[TBL] [Abstract][Full Text] [Related]
8. Transdermal fentanyl to parenteral morphine route switch and drug rotation in refractory cancer cachexia.
Alsirafy SA; Alabdullateef SH; Elyamany AM; Hassan AD; Almashiakhi M
BMJ Support Palliat Care; 2022 Jul; 12(e2):e184-e186. PubMed ID: 31492673
[TBL] [Abstract][Full Text] [Related]
9. The Opioid Rotation Ratio From Transdermal Fentanyl to "Strong" Opioids in Patients With Cancer Pain.
Reddy A; Yennurajalingam S; Reddy S; Wu J; Liu D; Dev R; Bruera E
J Pain Symptom Manage; 2016 Jun; 51(6):1040-5. PubMed ID: 26826675
[TBL] [Abstract][Full Text] [Related]
10. [Dose-finding for treatment with a transdermal fentanyl patch : Titration with oral transmucosal fentanyl citrate and morphine sulfate].
Mücke M; Conrad R; Marinova M; Cuhls H; Elsner F; Rolke R; Radbruch L
Schmerz; 2016 Dec; 30(6):560-567. PubMed ID: 27072143
[TBL] [Abstract][Full Text] [Related]
11. Exposure to Fentanyl After Transdermal Patch Administration for Cancer Pain Management.
Bista SR; Haywood A; Hardy J; Norris R; Hennig S
J Clin Pharmacol; 2016 Jun; 56(6):705-13. PubMed ID: 26381285
[TBL] [Abstract][Full Text] [Related]
12. Transdermal fentanyl for cancer pain: Trial sequential analysis of 3406 patients from 35 randomized controlled trials.
Wang DD; Ma TT; Zhu HD; Peng CB
J Cancer Res Ther; 2018; 14(Supplement):S14-S21. PubMed ID: 29578144
[TBL] [Abstract][Full Text] [Related]
13. Inappropriate use of high doses of transdermal fentanyl at admission to a palliative care unit.
Botterman J; Criel N
Palliat Med; 2011 Mar; 25(2):111-6. PubMed ID: 20937611
[TBL] [Abstract][Full Text] [Related]
14. A new once-a-day fentanyl citrate patch (Fentos Tape) could be a new treatment option in patients with end-of-dose failure using a 72-h transdermal fentanyl matrix patch.
Koike K; Terui T; Nagasako T; Horiuchi I; Machino T; Kusakabe T; Hirayama Y; Mihara H; Yamakage M; Kato J; Nishisato T; Ishitani K
Support Care Cancer; 2016 Mar; 24(3):1053-9. PubMed ID: 26248654
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of Fentanyl Citrate Patch, Including a Low-Dose 0.5 mg Formulation, in Opioid-Naïve Patients with Cancer Pain.
Yamaguchi S; Uchida E; Terahara T; Okawa K; Hashimoto F; Tanaka Y
Clin Drug Investig; 2020 Nov; 40(11):1041-1052. PubMed ID: 32886320
[TBL] [Abstract][Full Text] [Related]
16. Factors predicting requirement of high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone in patients with cancer pain.
Kanbayashi Y; Hosokawa T; Okamoto K; Fujimoto S; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Miki T; Taniwaki M
Clin J Pain; 2011 Oct; 27(8):664-7. PubMed ID: 21471811
[TBL] [Abstract][Full Text] [Related]
17. Constipation and the use of laxatives: a comparison between transdermal fentanyl and oral morphine.
Radbruch L; Sabatowski R; Loick G; Kulbe C; Kasper M; Grond S; Lehmann KA
Palliat Med; 2000 Mar; 14(2):111-9. PubMed ID: 10829145
[TBL] [Abstract][Full Text] [Related]
18. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.
Sittl R; Likar R; Nautrup BP
Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486
[TBL] [Abstract][Full Text] [Related]
19. A comparison of the resources used in advanced cancer care between two different strong opioids: an analysis of naturalistic practice in the UK.
Guest JF; Ruiz FJ; Russ J; Gupta RD; Mihai A; Greener M
Curr Med Res Opin; 2005 Feb; 21(2):271-80. PubMed ID: 15801998
[TBL] [Abstract][Full Text] [Related]
20. [Optimal conversion ratio of oral morphine to transdermal fentanyl patches to the cancer pain].
Ogawa J; Nakamura K; Iizuka K; Sekizuka M; Yamamoto K; Horiuchi R
Yakugaku Zasshi; 2009 Mar; 129(3):335-40. PubMed ID: 19252390
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
